Publications by authors named "Anneleis Willett"
Article Synopsis
- Appendiceal adenocarcinoma (AA) is a rare cancer with few treatment options, especially for patients who can't have surgery, leading researchers to test a combination therapy of atezolizumab and bevacizumab (Atezo+Bev).
- In a phase II study, the Atezo+Bev treatment demonstrated a 100% disease control rate and significantly longer progression-free survival (18.3 months) compared to traditional chemotherapy for colorectal cancer (4.4 months).
- The promising results suggest that Atezo+Bev could be an effective option for patients with unresectable AA, indicating a need for further research into this treatment approach.
Article Synopsis
- * Out of the patients, only 38.6% had enough tissue for successful genomic profiling, and 90.2% of these patients showed genomic alterations; however, only 40.9% had options for approved therapy based on those alterations.
- * While GP integration led to changes in therapy for a small percentage of patients, challenges like insufficient tissue and worsening health status highlighted the need for improved strategies in managing CUP.
Background: Cancer of unknown primary (CUP) is an aggressive rare malignancy with limited treatment options. Data regarding clinical activity of immune checkpoint inhibitors in CUP is lacking. Therefore, we evaluated the efficacy of pembrolizumab, a programmed cell death-1 inhibitor, in patients with CUP.
View Article and Find Full Text PDFMalignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade (AtezoBev) was assessed in 20 patients with advanced and unresectable MPeM with progression or intolerance to prior platinum-pemetrexed chemotherapy.
View Article and Find Full Text PDFPurpose: Prognostic uncertainty is a major challenge for cancer of unknown primary (CUP). Current models limit a meaningful patient-provider dialogue. We aimed to establish a nomogram for predicting overall survival (OS) in CUP based on robust clinicopathologic prognostic factors.
View Article and Find Full Text PDF